Evidence map›Paper›PMID 39306232›Full record

ArticleJournal of cardiac failure2025

Should We Systematically Screen for the Amyloidogenic V142I Variant?

Jessica A Regan, Michel G Khouri, Opeyemi A Olabisi, Kevin M Alexander, Sadiya S Khan, Svati H Shah, Senthil Selvaraj

Abstract read
In one paragraph

Article in Journal of cardiac failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jessica A ReganDivision of Cardiology, Duke University School of Medicine, Durham, NC; Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, NC.
Michel G KhouriDivision of Cardiology, Duke University School of Medicine, Durham, NC.
Opeyemi A OlabisiDuke Molecular Physiology Institute, Duke University School of Medicine, Durham, NC; Division of Nephrology, Duke University Hospital, Durham, NC.
Kevin M AlexanderDivision of Cardiovascular Medicine, Stanford University, Stanford University School of Medicine, Stanford, CA.
Sadiya S KhanDepartment of Medicine (Cardiology), Northwestern University Feinberg School of Medicine, Chicago, IL; Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL.
Svati H ShahDivision of Cardiology, Duke University School of Medicine, Durham, NC; Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, NC; Duke Center for Precision Health, Duke University School of Medicine, Durham NC.
Senthil SelvarajDivision of Cardiology, Duke University School of Medicine, Durham, NC; Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, NC. Electronic address: senthil.selvaraj@duke.edu.

Funding

JAK-STAT Inhibition to Reduce Racial Disparities in Kidney DiseaseR01MD016401 · NIMHD · DUKE UNIVERSITY · PI OLABISI, OPEYEMI AYODEJI · 2021 to 2025
$3.5M
Dissecting the Ketone Metabolic Axis in Heart Failure with Reduced Ejection FractionK23HL161348 · NHLBI · DUKE UNIVERSITY · PI Senthil Selvaraj · 2022 to 2026
$1.0M
Age-Related Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Exercise ResponsivenessK38HL175026 · NHLBI · DUKE UNIVERSITY · PI REGAN, JESSICA ANN · 2024 to 2025
$210k
NHLBI NIH HHS K23 HL161348NHLBI NIH HHS K38 HL175026NIMHD NIH HHS R01 MD016401
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AmyloidosistransthyretinV142I

Identifiers

PMID39306232
PMCPMC12163913

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.